COMMUNIQUÉ DE PRESSE
par Marinomed Biotech AG
EQS-Adhoc: Cessation of operations and closure of the company
EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Insolvency
Cessation of operations and closure of the company
24-Sep-2026 / 10:37 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
Korneuburg, Austria, 24th September 2026 – Marinomed Biotech AG: Cessation of operations and closure of the company
Marinomed Biotech AG announces that the administrator, Dr. Ulla Reisch, filed a motion to close the business during the court hearing on September 24, 2026. Consequently, the insolvency court ordered the closure of Marinomed Biotech AG’s business operations. It was not possible to ensure the continuation of the business because ongoing operations failed to yield the necessary positive results, a planned sale of licensing rights could not be concluded in time, and discussions with potential investors had been unsuccessful to date. The insolvency administrator will now initiate a sale of the company's assets. The company will provide updates on further legal and operational steps as soon as reliable information becomes available.
+++ End of ad-hoc announcement +++
Marinomed Biotech AG announces that the administrator, Dr. Ulla Reisch, filed a motion to close the business during the court hearing on September 24, 2026. Consequently, the insolvency court ordered the closure of Marinomed Biotech AG’s business operations. It was not possible to ensure the continuation of the business because ongoing operations failed to yield the necessary positive results, a planned sale of licensing rights could not be concluded in time, and discussions with potential investors had been unsuccessful to date. The insolvency administrator will now initiate a sale of the company's assets. The company will provide updates on further legal and operational steps as soon as reliable information becomes available.
+++ End of ad-hoc announcement +++
End of Inside Information
24-Sep-2026 CET/CEST News transmitted by EQS Group
View original content: EQS News
| Language: | English |
| Company: | Marinomed Biotech AG |
| Hovengasse 25 | |
| 2100 Korneuburg | |
| Austria | |
| Phone: | +43 2262 90300 |
| E-mail: | office@marinomed.com |
| Internet: | www.marinomed.com |
| ISIN: | ATMARINOMED6 |
| WKN: | A2N9MM |
| Listed: | Regulated Unofficial Market in Dusseldorf |
| LEI Code: | 529900GN3B1EN80XF405 |
| EQS News ID: | 2404696 |
| End of Announcement | EQS News Service |
2404696 24-Sep-2026 CET/CEST